Abstract 3197
Background
Cardiac sarcoma is a rare tumor. Currently, there is a lack of data on the genomic profiling in Chinese cardiac sarcoma patients. In this study, we analyzed the genomic alterations and prognostic biomarkers of this kind of patients.
Methods
Total FFPE samples of 26 cardiac sarcoma patients who received operation during 2010 to 2018 were enrolled in this study. FFPE samples from these patients were collected for WES (Whole Exome Sequencing). Genomic alterations including single base substitution, copy number variations, gene fusions and rearrangement were assessed. Tumor mutational burden (TMB) was also analyzed by NGS algorithm.
Results
The cohort of 26 cardiac sarcoma patients included 13 males and 13 females with a median age of 54 (range 27-68). Patients were followed up for 8 years (10 patients) or until patients died (16 patients). The median overall survive (OS) was 14 months. This cohort included 18 angiosarcomas (AS), 6 intimal sarcomas (IS), 1 liposarcoma (LPS) and 1 synovial sarcoma (SS). The most commonly altered genes were KDR (35%), MDM2 (31%), FRS2 (27%), KMT2D (23%), CKD4 (23%), GLI1 (23%) and TERT (23%). Several druggable genomic alterations including amplification of CDK4 (6/26), KIT (5/26), KDR (2/26), PDGFRA (2/26), ERBB3 (1/26), and mutations of BRAF (1/26), BRCA1 (1/26) and PTEN (1/26) were found. AS patients with alterations of TP53, TRMT10C, ALMS1, CCDC157, CCNJL, KIAA2026 or OSBPL7 gene had a poor prognosis with a median OS of 3 months, while AS patients without alterations of any those genes had a median OS of 21 months. Interestingly, MDM2 amplification was only found in IS and LPS, but not in AS, which was confirmed by FISH analysis. The median TMB was 29 muts/Mb (2.3-56.5 muts/Mb) in this cohort.
Conclusions
Our study firstly revealed the genomic profiling of Chinese cardiac sarcoma patients. Several genes may be relevant with prognosis in AS, and MDM2 amplification may be a potential biomarker to distinguish between different subtypes. Most of the patients (92.3%) presented high TMB value which may potentially benefitted to immunotherapy. Due to limited number of patients, the correlation of gene mutations with clinical features need to be further analyzed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract
5638 - Incidence of Vascular Thromboembolism Events in Cancer Patients Receiving Immunotherapy: A Single Institution Experience.
Presenter: Laura Gutiérrez Sainz
Session: Poster Display session 1
Resources:
Abstract
5182 - High Incidence of Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma.
Presenter: Alaa Abufara
Session: Poster Display session 1
Resources:
Abstract
1504 - Weight Loss over Time in Non-Small Cell Lung Cancer: Results from a Landmark Analysis of 800+ Prospectively-Treated Patients
Presenter: Jennifer Le-rademacher
Session: Poster Display session 1
Resources:
Abstract
3972 - The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC).
Presenter: Salvatore Paiella
Session: Poster Display session 1
Resources:
Abstract
2313 - Impact of Timing and Technique of Gastrostomy Placement on the Outcome of Patients (pts) with Head and Neck Cancer (HNC)
Presenter: M Julia Lostes Bardaji
Session: Poster Display session 1
Resources:
Abstract
5219 - Clinical & nutritional determinants of quality of life in patients with incurable cancer
Presenter: Louise Daly
Session: Poster Display session 1
Resources:
Abstract
4075 - Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer
Presenter: In Gyu Hwang
Session: Poster Display session 1
Resources:
Abstract
4159 - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).
Presenter: Ilaria Trestini
Session: Poster Display session 1
Resources:
Abstract
1210 - Sarcopenia and pretreatment anemia as prognostic factors for patients with localized muscle invasive bladder cancer treated by neoadjuvant chemotherapy and radical cystectomy
Presenter: Emilien Billon
Session: Poster Display session 1
Resources:
Abstract